Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Akron Children's Hospital
2041
mi
from 98109
Akron, OH
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Akron Children's Hospital
2041
mi
from 98109
Akron, OH
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Cincinnati Children's Hospital Medical Center
1966
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Rainbow Babies and Children's Hospital
2020
mi
from 98109
Cleveland, OH
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Rainbow Babies and Children's Hospital
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Nationwide Children's Hospital
2008
mi
from 98109
Columbus, OH
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Nationwide Children's Hospital
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program The Children's Medical Center
1959
mi
from 98109
Dayton, OH
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program The Children's Medical Center
1959
mi
from 98109
Dayton, OH
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Oregon Health & Sciences University
146
mi
from 98109
Portland, OR
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Oregon Health & Sciences University
146
mi
from 98109
Portland, OR
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Hershey Medical Center
2293
mi
from 98109
Hershey, PA
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Hershey Medical Center
2293
mi
from 98109
Hershey, PA
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Sanford USD Medical Center
1263
mi
from 98109
Sioux Falls, SD
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Sanford USD Medical Center
1263
mi
from 98109
Sioux Falls, SD
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program University of Tennessee
1864
mi
from 98109
Memphis, TN
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program University of Tennessee
1864
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Dell Children's Medical Center of Central Texas
1770
mi
from 98109
Austin, TX
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Dell Children's Medical Center of Central Texas
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
University of Utah
703
mi
from 98109
Salt Lake City, UT
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
University of Utah
703
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of the King's Daughters
2430
mi
from 98109
Norfolk, VA
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of the King's Daughters
2430
mi
from 98109
Norfolk, VA
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center Medical College of Virginia
2350
mi
from 98109
Richmond, VA
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center Medical College of Virginia
2350
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Seattle Children's Hospital
3
mi
from 98109
Seattle, WA
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Seattle Children's Hospital
3
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program University of Wisconsin
1615
mi
from 98109
Madison, WI
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program University of Wisconsin
1615
mi
from 98109
Madison, WI
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of Wisconsin
1681
mi
from 98109
Milwaukee, WI
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Children's Hospital of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program All Children's Hospital
mi
from 98109
Saint Petersburg, FL
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program All Children's Hospital
mi
from 98109
Saint Petersburg, FL
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program Cardinal Glennon Children's Hospital/Saint Louis University
mi
from 98109
Saint Louis, MO
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program Cardinal Glennon Children's Hospital/Saint Louis University
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated:  12/31/1969
CFF Care Center & Pediatric Program St. Louis Children's Hospital
mi
from 98109
Saint Louis, MO
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Status: Enrolling
Updated: 12/31/1969
CFF Care Center & Pediatric Program St. Louis Children's Hospital
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
A Phase I Trial With Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
A Phase I Trial With Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Status: Enrolling
Updated:  12/31/1969
Mstcvs-Qc
1902
mi
from 98109
Ann Arbor, MI
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Status: Enrolling
Updated: 12/31/1969
Mstcvs-Qc
1902
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Status: Enrolling
Updated:  12/31/1969
Mstcvs-Qc
1902
mi
from 98109
Ann Arbor, MI
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Status: Enrolling
Updated: 12/31/1969
Mstcvs-Qc
1902
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
Status: Enrolling
Updated:  12/31/1969
Sonoma West Medical Center
638
mi
from 98109
Sebastopol, CA
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
Status: Enrolling
Updated: 12/31/1969
Sonoma West Medical Center
638
mi
from 98109
Sebastopol, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
BCG Oncology
1107
mi
from 98109
Phoenix, AZ
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
BCG Oncology
1107
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of California San Diego, Moores Cancer Center
1049
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
UCLA Institute of Urological Oncology
962
mi
from 98109
Los Angeles, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
UCLA Institute of Urological Oncology
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of California Davis Cancer Center
628
mi
from 98109
Sacramento, CA
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of California Davis Cancer Center
628
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
University of Chicago, Department of Surgery, Section of Urology
1733
mi
from 98109
Chicago, IL
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
University of Chicago, Department of Surgery, Section of Urology
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center, Department of Urologic Surgery
1970
mi
from 98109
Nashville, TN
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center, Department of Urologic Surgery
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
2079
mi
from 98109
Birmingham, AL
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
994
mi
from 98109
Irvine, CA
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
994
mi
from 98109
Irvine, CA
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
1062
mi
from 98109
San Diego, CA
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
1062
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
1032
mi
from 98109
Centennial, CO
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
1032
mi
from 98109
Centennial, CO
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Site
1367
mi
from 98109
Omaha, NE
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Site
1367
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
1929
mi
from 98109
Toledo, OH
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
1929
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
1660
mi
from 98109
Frisco, TX
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
1660
mi
from 98109
Frisco, TX
Click here to add this to my saved trials
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  12/31/1969
Octapharma Research Site
mi
from 98109
Edmonton,
Study of Octanorm Subcutaneous IG in Patients With PID
Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 12/31/1969
Octapharma Research Site
mi
from 98109
Edmonton,
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
San Diego Clinical Trials
1063
mi
from 98109
San Diego, CA
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
San Diego Clinical Trials
1063
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
2527
mi
from 98109
Tampa, FL
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Columbus Regional Research Institute
2008
mi
from 98109
Columbus, OH
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Columbus Regional Research Institute
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Nephrology
5879
mi
from 98109
Gabrovo,
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Nephrology
5879
mi
from 98109
Gabrovo,
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
1930
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated:  12/31/1969
Sunrise Hospital and Medical Centre
875
mi
from 98109
Las Vegas, NV
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Status: Enrolling
Updated: 12/31/1969
Sunrise Hospital and Medical Centre
875
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
Safety and Immunogenicity of Q Fever Vaccine
Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii
Status: Enrolling
Updated:  12/31/1969
Special Immunizations Program, Division of Medicine, USAMRIID
2285
mi
from 98109
Fort Deterick, MD
Safety and Immunogenicity of Q Fever Vaccine
Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii
Status: Enrolling
Updated: 12/31/1969
Special Immunizations Program, Division of Medicine, USAMRIID
2285
mi
from 98109
Fort Deterick, MD
Click here to add this to my saved trials
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults
Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Status: Enrolling
Updated:  12/31/1969
Coastal Clinical Research Inc
2145
mi
from 98109
Mobile, AL
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults
Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Status: Enrolling
Updated: 12/31/1969
Coastal Clinical Research Inc
2145
mi
from 98109
Mobile, AL
Click here to add this to my saved trials
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults
Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
2526
mi
from 98109
DeLand, FL
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults
Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
2526
mi
from 98109
DeLand, FL
Click here to add this to my saved trials